BridgeBio Pharma/BBIO

13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX

About BridgeBio Pharma

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy. The company focus on genetic diseases because they exist at the intersection of high unmet patient need and tractable biology.

Ticker

BBIO

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Palo Alto, United States

Employees

553

BridgeBio Pharma Metrics

BasicAdvanced
$4.7B
Market cap
-
P/E ratio
-$3.18
EPS
1.03
Beta
-
Dividend rate
$4.7B
1.03
6.371
6.141
-166.294
-166.732
-5.59%
-40.08%
48.58%
19.29
-4.44
-4.34
-6.96
181.05%
11.60%
192.77%
-9.01%

What the Analysts think about BridgeBio Pharma

Analyst Ratings

Majority rating from 15 analysts.
Buy

BridgeBio Pharma Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-16.67% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$211M
12,317.65%
Net income
-$35M
-79.06%
Profit margin
-16.67%
-99.83%

BridgeBio Pharma Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 71.92%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.98
-$1.08
-$0.96
-$0.20
-
Expected
-$0.83
-$0.82
-$0.91
-$0.71
-$1.05
Surprise
17.60%
32.42%
5.44%
-71.92%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for BridgeBio Pharma stock?

BridgeBio Pharma (BBIO) has a market cap of $4.7B as of July 04, 2024.

What is the P/E ratio for BridgeBio Pharma stock?

The price to earnings (P/E) ratio for BridgeBio Pharma (BBIO) stock is 0 as of July 04, 2024.

Does BridgeBio Pharma stock pay dividends?

No, BridgeBio Pharma (BBIO) stock does not pay dividends to its shareholders as of July 04, 2024.

When is the next BridgeBio Pharma dividend payment date?

BridgeBio Pharma (BBIO) stock does not pay dividends to its shareholders.

What is the beta indicator for BridgeBio Pharma?

BridgeBio Pharma (BBIO) has a beta rating of 1.03. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell BridgeBio Pharma stock

Buy or sell BridgeBio Pharma stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing